|
|
Post by mango on Mar 5, 2021 9:51:53 GMT -5
The report told us— Average starting HbA1c: 10.4 Average lowest HbA1c attained: 6.6 Total drop in HbA1c: 3.8 in about 104 days. That is significant. All done using Afrezza. Sure, CGMs help guide the patient, but it is the Afrezza that is doing the magic. Also something else pretty remarkable worth mentioning from the report is: While these gross numbers are impressive, perhaps more impressive is that 72% of patients attained an HbA1c of 7 or below. Majority of PWD don’t reach that level, which is set by ADA, and is actually still much too high as it is still in the red zone for microvascular damage, oxidative stress and so on. Vdex goes beyond the proven treat to failure protocols of ADA. So please tell me, why was that reported? About 10years ago Sam Finta reported similar numbers. Back then it was new and noteworthy! Now it only shows how Afrezza works, which is helping VDex. What is missing is any benefit of VDex for Mannkind. 76 patients over a year? We are getting more than 4fold that number per week!
What is the demonstrated benefit for Afrezza users to go that route? Obviously there are other ways to get Afrezza covered by insurance and use it correctly. There might be facts how VDex contributes to Afrezza, but why don´t they present them?
Any emtpy post (full of promises) seems to speak quite loudly!
The demonstrated benefit of PWD going the Vdex route versus the traditional Endo or PC route is obvious—they receive significantly better care and achieve significantly better results. I’m not sure you even understand what you just asked. 🤨 |
|
|
|
Post by morfu on Mar 5, 2021 9:56:37 GMT -5
76 people where the patients in the study..the more studies you do the more White Papers you write the more people see the results of those studies. Mannkind manufactures the product. I remember three of the Mannkind reps being super excited about the first White Paper. There was even a conference call about what parts of it they could use and couldn’t use in marketing to doctors. Hmm, I wrote:
>> Back then it was new and noteworthy! >> There might be facts how VDex contributes to Afrezza, but why don´t they present them?
76 people were helped though VDex using Afrezza in 2020. And they have 4 clinics, each patient gets 45mins personal time and VDex is committed to help with insurance coverage.
Are there any other facts or numbers you want to add to how VDex helps Mannkind than this?
The old question still stands: Is any proof for the claimed significant impact of VDex on Afrezza sales AND retention by VDex? (I stated before that I estimate VDex impact on Afrezza sales to be at most 15% and there is now proof of any better retention)
Personally, I believe there are more efficient ways to become an Afrezza patient and in medical business efficiency is key, so beside your tireless advertising that company seems doomed in the long run as doctors and patients figure it out without VDex.
|
|
|
|
Post by morfu on Mar 5, 2021 9:58:28 GMT -5
So please tell me, why was that reported? About 10years ago Sam Finta reported similar numbers. Back then it was new and noteworthy! Now it only shows how Afrezza works, which is helping VDex. What is missing is any benefit of VDex for Mannkind. 76 patients over a year? We are getting more than 4fold that number per week!
What is the demonstrated benefit for Afrezza users to go that route? Obviously there are other ways to get Afrezza covered by insurance and use it correctly. There might be facts how VDex contributes to Afrezza, but why don´t they present them?
Any emtpy post (full of promises) seems to speak quite loudly!
The demonstrated benefit of PWD going the Vdex route versus the traditional Endo or PC route is obvious—they receive significantly better care and achieve significantly better results. I’m not sure you even understand what you just asked. 🤨 I do not see how that is demonstrated. It shows that the PWD should use Afrezza and learn how to use it, but what is the benefit of VDex therin? |
|
|
|
Post by mango on Mar 5, 2021 10:25:34 GMT -5
The demonstrated benefit of PWD going the Vdex route versus the traditional Endo or PC route is obvious— they receive significantly better care and achieve significantly better results. I’m not sure you even understand what you just asked. 🤨 I do not see how that is demonstrated. It shows that the PWD should use Afrezza and learn how to use it, but what is the benefit of VDex therin? I highlighted the benefit therein for you. 🙂 |
|
|
|
Post by morfu on Mar 5, 2021 10:49:57 GMT -5
I do not see how that is demonstrated. It shows that the PWD should use Afrezza and learn how to use it, but what is the benefit of VDex therin? I highlighted the benefit therein for you. 🙂 Oh, then I am afraid that you are wrong! The claim that they receive better care is not covered in that paper and the results come form Afrezza not VDex.
|
|
|
|
Post by longliner on Mar 5, 2021 10:52:52 GMT -5
I am appreciative although the whole HfM fiasco severely pissed me off. The fact is our TRx numbers are still anemic, VDEX or not. What I am hopeful of (and wish I could be confident of) is that VDEX is rewarded richly for their vision and perseverence once the headwinds abate that are holding both VDEX and MNKD back. What I do not assume is that the biggest headwinds are VDEX’s lack of securing special discounts, manufacturing rights, or exclusivity of sales territories. Those would no doubt help VDEX secure access to capital on better terms and perhaps greater amounts, and help them with their business plan which would in turn help Mannkind, but those are not minor concessions and given the Mannkind disastrous experience with their previous marketing agreement in which they secured a commitment for more than $1B, they can perhaps be forgiven an extra reluctance. PC thanks for bringing this forward. I have seen recently in discussion here the two issues being conflated. Appreciating the hard work VDex is putting toward helping the sick heal is quite a different discussion than the HFM move to place board members etc.. I, like you, was not happy with what transpired with the HFM group. I am however extremely pleased with the effort and awareness VDex has put forth and brings to both Afrezza and diabetes. As Rooks pointed out, one is water under the bridge the other (thankfully) is ongoing. |
|
|
|
Post by sportsrancho on Mar 5, 2021 11:00:39 GMT -5
I stand by my feelings that Bill and Harlan would’ve been great on the Board of Directors. And Bill stands by his opinion that Mannkind is marketing the drug in the wrong way.
But it is what it is at this point. The proof is in the pudding.
|
|
|
|
Post by sportsrancho on Mar 5, 2021 11:04:21 GMT -5
Look I’m not blaming anyone ...the FDA puts restrictions on companies, we don’t have those restrictions ...we can dose off-label. And with Afrezza that makes a tremendous amount of difference in the results.
|
|
|
|
Post by longliner on Mar 5, 2021 11:05:51 GMT -5
Look I’m not blaming anyone ...the FDA puts restrictions on companies, we don’t have those restrictions ...we can dose off-label. And with Afrezza that makes a tremendous amount of difference in the results. Keep up the good work! |
|
|
|
Post by longliner on Mar 5, 2021 11:08:59 GMT -5
I am really looking forward to the UTHR expedited application hitting the FDA's desk! FUD will become a bit "dicey". I don't think Martine's dialogue is quite so easy to manipulate on the "interweb's" as our little companies has been.  |
|
|
|
Post by sportsrancho on Mar 5, 2021 11:11:18 GMT -5
It can’t come soon enough, I am looking forward to that run up!
|
|
|
|
Post by cretin11 on Mar 5, 2021 11:42:58 GMT -5
I stand by my feelings that Bill and Harlan would’ve been great on the Board of Directors. And Bill stands by his opinion that Mannkind is marketing the drug in the wrong way. But it is what it is at this point. The proof is in the pudding. The proof is indeed in the pudding, and Bill’s aforementioned assertion has been proven, in spades. And there were some contextual underpinnings of the HFM situation of which some folks here are unaware. Bill and Harland would’ve been outstanding additions to the Board. |
|
|
|
Post by ppallap on Mar 5, 2021 17:16:38 GMT -5
Off topic, but how about adding artificial flavors to inhalable insulin ? Strawberry, chocolate etc. will certainly attract many patients especially young ones after pediatric trial. Pardon my ignorance, but is that even possible to do for such drugs ?
|
|
|
|
Post by mango on Mar 5, 2021 17:36:09 GMT -5
I highlighted the benefit therein for you. 🙂 Oh, then I am afraid that you are wrong! The claim that they receive better care is not covered in that paper and the results come form Afrezza not VDex.
#1 The claim they receive better care is based on all available evidence. Social media, results, patient testimonies, attention to detail, provider-to-patient time, etc. #2 The physiological results come from Afrezza, but if not inhaled properly, dosed properly, timed properly, and understood properly the results will be significantly different. We know this for a fact—which is why Vdex has such high retention and significant results compared to a normal PC and Endo clinic. Stop being difficult for the sake of being difficult. You and everyone else knows what you are doing. |
|
|
|
Post by BD on Mar 5, 2021 17:45:58 GMT -5
Stop being difficult for the sake of being difficult. You and everyone else knows what you are doing. I don't. Because my clairvoyance headset is in the shop right now. |
|
